Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

November 14, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News Stories for 2015

Shelley Wood

December 29, 2015

News Opinion Editor's Corner

Las 10 Noticias de TCTMD Más Leídas de 2015

Shelley Wood

December 29, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Daily News

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

June 25, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Daily News

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

June 25, 2015

Presentation

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Presenter: Charles V. Pollack Jr

June 24, 2015

Advertisement

New RE-VERSE AD™ Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind®) in Pradaxa® Patients with Gastrointestinal Bleeding or Needing Emergency Surgery

TCTMD’s Top 10 Most Popular News Stories for 2015

Las 10 Noticias de TCTMD Más Leídas de 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

RE-VERSE AD: El Antídoto de Dabigatran, Seguro y Eficaz en un Análisis Provisional

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

RE-VERSE AD：中期分析表明达比加群中和剂似乎安全有效

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content